Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells $10,328.00 in Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) CFO Molly Henderson sold 1,291 shares of the business's stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $8.00, for a total transaction of $10,328.00. Following the completion of the sale, the chief financial officer now owns 98,156 shares in the company, valued at $785,248. The trade was a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Phathom Pharmaceuticals Price Performance

Shares of NASDAQ PHAT traded down $0.37 during mid-day trading on Friday, reaching $7.45. The company's stock had a trading volume of 2,475,979 shares, compared to its average volume of 922,597. The stock has a fifty day moving average of $12.11 and a two-hundred day moving average of $13.07. Phathom Pharmaceuticals, Inc. has a 52 week low of $6.07 and a 52 week high of $19.71. The firm has a market capitalization of $509.41 million, a PE ratio of -1.31 and a beta of 0.56.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of PHAT. Huntington National Bank increased its stake in shares of Phathom Pharmaceuticals by 62.2% in the 3rd quarter. Huntington National Bank now owns 1,471 shares of the company's stock worth $27,000 after acquiring an additional 564 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Phathom Pharmaceuticals by 41.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company's stock worth $43,000 after buying an additional 722 shares during the period. US Bancorp DE lifted its stake in Phathom Pharmaceuticals by 28.6% in the third quarter. US Bancorp DE now owns 5,248 shares of the company's stock worth $95,000 after acquiring an additional 1,166 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in Phathom Pharmaceuticals by 10.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,941 shares of the company's stock worth $144,000 after acquiring an additional 1,339 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Phathom Pharmaceuticals by 42.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,071 shares of the company's stock valued at $104,000 after buying an additional 2,987 shares in the last quarter. Institutional investors and hedge funds own 99.01% of the company's stock.

Analyst Upgrades and Downgrades

PHAT has been the topic of several analyst reports. HC Wainwright restated a "buy" rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a research note on Thursday, December 12th. Needham & Company LLC restated a "buy" rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a research report on Wednesday, December 11th.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.